This Action aims at using innovative translational research to identify colorectal cancer biomarkers for personalized medicine that will improve screening, early detection and disease follow-up, and attain better tumor profiling, state-of-the-art functional characterization of genetic variants and new therapy approaches
This meeting will focus on Tumor profiling (WG3). It will include a Management Committee meeting. Therefore, official MC members will be compulsory invited following COST regulations.
This congress is organized by some participants of our COST Action (María José Serrano, Juan José Díaz, Carmen Garrido, José Antonio Lorente) and we are disseminating it to other participants in case they may be interested.
Tuesday, 19 November 2019